Key Takeaways and Looking Ahead

Author(s):

Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.

EP: 1.Treatment Landscape and Sequencing of Therapies

EP: 2.Treatment Timelines Related to Disease State and Use of Monotherapy

EP: 3.Genetic Testing – Germline

EP: 4.Recent Data on ARPI-Based Combination Regimens

EP: 5.Genetic Testing – Somatic

EP: 6.ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP: 7.Use of Bone Protection Agents

EP: 8.ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

EP: 9.ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

EP: 10.ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

Now Viewing

EP: 11.Key Takeaways and Looking Ahead

ALL: Based on the new data and your clinical experience, what are the most important takeaways regarding the management of patients with metastatic prostate cancer?
ALL: What are the most pressing unmet needs or areas for future research in the treatment of advanced prostate cancer that clinicians should keep an eye on?
ALL: Do you have any additional advice or recommendations for how to optimize the care of patients with metastatic prostate cancer?